NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for use in oncology and immunology, today announced oral and poster presentations of key preclinical data relating to certain of its drug development programs, including KTN3379, KTN0158, ALK-ADC and MET, at the American Association for Cancer Research (AACR) Annual Meeting, which will take place in New Orleans, Louisiana, April 16-20, 2016.
